Robin Traufler
Acute Care · Columbia, SCNPI 1669474490
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,770 of the $11,502 with a category attached, or 76.2%. 27 manufacturers reported payments, led by Daxor Corporation at 24.8% of the total. Reporting peaked in 2022 at $4,662 and has fallen 62.9% since, to $1,729 in 2025. Among acute care clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 466 payments — averaging $24.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daxor Corporation$3K
- Abbott$2K
- Alnylam Pharmaceuticals Inc.$995
- Boston Scientific$751
- Novartis$740
- Merck$516
- plus $4K from 21 others
What the payments were for
- Speaking & faculty fees$2,39321%
- Travel & lodging$3403%
- Food & beverage$8,77076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daxor Corporation | 8 | $2,850 |
| Abbott | 124 | $1,979 |
| Alnylam Pharmaceuticals Inc. | 43 | $995 |
| Boston Scientific | 18 | $751 |
| Novartis | 59 | $740 |
| Merck | 29 | $516 |
| Actelion Pharmaceuticals US, Inc. | 23 | $510 |
| Pfizer | 25 | $497 |
| Boehringer Ingelheim | 26 | $492 |
| AstraZeneca | 25 | $431 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $364 |
| Cvrx, Inc. | 11 | $331 |
| Bayer | 14 | $235 |
| Scpharmaceuticals Inc. | 8 | $143 |
| Impulse Dynamics (USA) Inc. | 9 | $138 |
| Bridgebio Pharma, Inc. | 3 | $86 |
| Novo Nordisk | 4 | $84 |
| Johnson & Johnson | 5 | $82 |
| E.r. Squibb & Sons, L.L.C. | 5 | $80 |
| Vifor Pharma, Inc. | 2 | $39 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Recor Medical Inc | 1 | $25 |
| Edwards Lifesciences | 1 | $23 |
| Atricure, Inc. | 1 | $22 |
| Nuwellis, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BVA-100$2,732
- WATCHMAN Access System$368
- UPTRAVI$124
- OPSUMIT$124
- Barostim Neo System$104
How this compares
$11,502 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $50,869 |
| EliquisApixaban | 30 | $25,453 |
| FarxigaDapagliflozin Propanediol | 16 | $14,767 |
| EntrestoSacubitril/Valsartan | 13 | $13,565 |
| Bumetanide | 45 | $2,735 |
| Amiodarone Hcl | 30 | $633 |
| Digoxin | 43 | $566 |
| Atorvastatin Calcium | 39 | $390 |
| Valsartan | 20 | $324 |
| Metoprolol Succinate | 34 | $283 |
| Spironolactone | 19 | $99 |
| Furosemide | 30 | $71 |
| Carvedilol | 17 | $57 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $492 | $50,86962 claims |
| PfizerEliquis | $497 | $25,45330 claims |
| AstraZenecaFarxiga | $431 | $14,76716 claims |
| NovartisEntresto | $740 | $13,56513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.
Other acute care in Columbia
- Michael GajewskiColumbia$62K
- Micheal BungerColumbia$15K
- Linda VanduysColumbia$7K
- Aziz PetiwalaColumbia$7K
- Christina AdkinsColumbia$6K
- Brandon PalmerColumbia$6K
- Sarah Ford-SightlerColumbia$6K
- Jessica WheelerColumbia$6K
- Stacy SandersColumbia$6K
- Jazmine PorterfieldColumbia$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.